

Bo AhrÃ©n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7087299/publications.pdf>

Version: 2024-02-01

433
papers

24,046
citations

6613
79
h-index

11308
136
g-index

443
all docs

443
docs citations

443
times ranked

16431
citing authors

#	ARTICLE	IF	CITATIONS
1	Temporal Patterns of Glucagon and Its Relationships with Glucose and Insulin following Ingestion of Different Classes of Macronutrients. <i>Nutrients</i> , 2022, 14, 376.	4.1	6
2	Glucoseâ€dependent insulinotropic polypeptide secretion after oral macronutrient ingestion: The human literature revisited and a systematic study in model experiments in mice. <i>Journal of Diabetes Investigation</i> , 2022, , .	2.4	4
3	The Glucose Sensitivity of Insulin Secretion-Lessons from In Vivo and In Vitro Studies in Mice. <i>Biomolecules</i> , 2022, 12, 976.	4.0	2
4	The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice. <i>Peptides</i> , 2021, 135, 170434.	2.4	7
5	Glucose effectiveness: Lessons from studies on insulinâ€independent glucose clearance in mice. <i>Journal of Diabetes Investigation</i> , 2021, 12, 675-685.	2.4	16
6	Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test. <i>Frontiers in Endocrinology</i> , 2021, 12, 611147.	3.5	15
7	Glucoseâ€lowering action through targeting islet dysfunction in typeÂ2 diabetes: Focus on dipeptidyl peptidaseâ€4 inhibition. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1128-1135.	2.4	8
8	The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice: Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice. <i>Frontiers in Endocrinology</i> , 2021, 12, 665537.	3.5	3
9	Impact of Incretin Hormone Receptors on Insulin-Independent Glucose Disposal in Model Experiments in Mice. <i>Frontiers in Endocrinology</i> , 2021, 12, 680153.	3.5	7
10	Hepatic and Extrahepatic Insulin Clearance in Mice with Double Deletion of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Receptors. <i>Biomedicines</i> , 2021, 9, 973.	3.2	1
11	Glucagon-like peptide-1 and beta cell glucose sensitivity - a glucose ramp study in mice. <i>Peptides</i> , 2021, 146, 170650.	2.4	1
12	Islet adaptation in GIP receptor knockout mice. <i>Peptides</i> , 2020, 125, 170152.	2.4	3
13	Persistent whole day meal effects of three dipeptidyl peptidaseâ€4 inhibitors on glycaemia and hormonal responses in metforminâ€treated type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 590-598.	4.4	9
14	Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00141.	2.4	1
15	The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors. <i>Journal of the Endocrine Society</i> , 2020, 4, bvz036.	0.2	7
16	Glucagonâ€like peptideâ€1 receptor agonists for type 2 diabetes: A rational drug development. <i>Journal of Diabetes Investigation</i> , 2019, 10, 196-201.	2.4	32
17	Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 25-31.	3.4	14
18	DPP-4 Inhibition and the Path to Clinical Proof. <i>Frontiers in Endocrinology</i> , 2019, 10, 376.	3.5	68

#	ARTICLE	IF	CITATIONS
19	Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 2171-2180.	8.6	54
20	Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections. <i>Diabetes Therapy</i> , 2019, 10, 2115-2130.	2.5	15
21	Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDIâ€liraglutide study 5). <i>Obesity Science and Practice</i> , 2019, 5, 130-140.	1.9	8
22	Insulin and incretin hormone responses to rapid versus slow ingestion of a standardized solid breakfast in healthy subjects. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00056.	2.4	6
23	Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2019, 316, R27-R37.	1.8	19
24	Different glucagon effects during DPPâ€4 inhibition versus SGLTâ€2 inhibition in metforminâ€treated type 2 diabetes patients. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1652-1658.	4.4	11
25	Effects on the glucagon response to hypoglycaemia during <scp>DPP</scp>â€4 inhibition in elderly subjects with type 2 diabetes: <scp>A</scp> randomized, placeboâ€controlled study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1911-1920.	4.4	5
26	DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes. <i>Molecular and Cellular Endocrinology</i> , 2018, 473, 186-193.	3.2	48
27	Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000464.	2.8	18
28	Effect of singleâ€dose <scp>DPP</scp>â€4 inhibitor sitagliptin on Î²â€cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drugâ€naïve, wellâ€controlled type 2 diabetes subjects. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1080-1085.	4.4	16
29	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2210-2219.	4.4	87
30	Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2018, 314, R639-R646.	1.8	12
31	Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. <i>Diabetes Research and Clinical Practice</i> , 2017, 126, 230-239.	2.8	22
32	Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice. <i>Physiological Reports</i> , 2017, 5, e13280.	1.7	16
33	Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1283-1285.	2.3	9
34	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 341-354.	11.4	307
35	Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice. <i>Peptides</i> , 2017, 88, 74-79.	2.4	28
36	Effects of <scp>DPP</scp>â€4 inhibitor linagliptin and <scp>GLP</scp>â€1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, openâ€label, 2â€arm parallel comparative, exploratory trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 442-447.	4.4	23

#	ARTICLE	IF	CITATIONS
37	Alain Ktorza, PhD. Diabetes, Obesity and Metabolism, 2017, 19, 3-3.	4.4	0
38	Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial. Diabetes Care, 2017, 40, 1573-1579.	8.6	119
39	Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring. Diabetes/Metabolism Research and Reviews, 2017, 33, e2879.	4.0	7
40	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Diabetes Research and Clinical Practice, 2017, 131, 49-60.	2.8	26
41	High-energy breakfast based on whey protein reduces body weight, postprandial glycemia and HbA 1C in Type 2 diabetes. Journal of Nutritional Biochemistry, 2017, 49, 1-7.	4.2	43
42	The Vildagliptin Experience â€“ 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. European Endocrinology, 2017, 13, 56.	1.5	7
43	Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes. Diabetes Care, 2016, 39, 242-249.	8.6	12
44	Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes. International Journal of Endocrinology, 2016, 2016, 1-4.	1.5	1
45	Evidence for neural contribution to islet effects of DPP-4 inhibition in mice. European Journal of Pharmacology, 2016, 780, 46-52.	3.5	8
46	Enhanced insulin sensitivity mediated by adipose tissue browning perturbs islet morphology and hormone secretion in response to autonomic nervous activation in female mice. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E81-E90.	3.5	0
47	Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes Therapy, 2016, 7, 583-590.	2.5	5
48	Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care, 2016, 39, 1693-1701.	8.6	159
49	Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. Diabetes, 2016, 65, 3473-3481.	0.6	137
50	Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 24-33.	4.4	29
51	Extrapaneatic contribution to glucose regulation by dipeptidyl peptidase 4 inhibition. Cardiovascular Endocrinology, 2016, 5, 82-85.	0.8	0
52	Incretin hormone receptors are required for normal beta cell development and function in female mice. Peptides, 2016, 79, 58-65.	2.4	10
53	Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse Î²-cell function in the GetGoal-M and GetGoal-S trials. Journal of Diabetes and Its Complications, 2016, 30, 1385-1392.	2.3	15
54	CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion. Diabetologia, 2016, 59, 1928-1937.	6.3	24

#	ARTICLE	IF	CITATIONS
55	Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. <i>Diabetologia</i> , 2016, 59, 907-917.	6.3	56
56	Evidence for time dependent variation of glucagon secretion in mice. <i>Peptides</i> , 2016, 76, 102-107.	2.4	2
57	Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. <i>Canadian Journal of Diabetes</i> , 2016, 40, 50-57.	0.8	27
58	The Islet and Metabolism Keep Time. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 3-5.	4.4	2
59	Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-7.	1.5	10
60	Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes. <i>Diabetes</i> , 2015, 64, 715-717.	0.6	7
61	Incretin Effect After Oral Amino Acid Ingestion in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1172-1176.	3.6	58
62	Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. <i>Diabetes and Metabolism</i> , 2015, 41, 6S3-6S8.	2.9	5
63	Incretin and Islet Hormone Responses to Meals of Increasing Size in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 561-568.	3.6	29
64	DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIPâ€“glucagon counterregulatory axis in mice. <i>Diabetologia</i> , 2015, 58, 1091-1099.	6.3	29
65	High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial. <i>Diabetologia</i> , 2015, 58, 912-919.	6.3	92
66	Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2015, 38, 1820-1826.	8.6	124
67	Glucagon and GLP-1 exhibit no synergistic enhancement of glucose-stimulated insulin secretion in mice. <i>Peptides</i> , 2015, 71, 66-71.	2.4	4
68	Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50Åyears?. <i>Diabetologia</i> , 2015, 58, 1740-1744.	6.3	11
69	Glucagon â€“ Early breakthroughs and recent discoveries. <i>Peptides</i> , 2015, 67, 74-81.	2.4	91
70	Deciphering the Hypoglycemic Glucagon Response: Development of a Graded Hyperinsulinemic Hypoglycemic Clamp Technique in Female Mice. <i>Endocrinology</i> , 2015, 156, 3866-3871.	2.8	6
71	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). <i>BMJ, The</i> , 2015, 351, h5364.	6.0	53
72	Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study. <i>PLoS ONE</i> , 2015, 10, e0129477.	2.5	18

#	ARTICLE	IF	CITATIONS
73	Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?. Diabetes Therapy, 2014, 5, 459-469.	2.5	12
74	Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets. Biochemical and Biophysical Research Communications, 2014, 453, 398-404.	2.1	25
75	Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2014, 16, 861-868.	4.4	24
76	HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin. Diabetes Care, 2014, 37, 2141-2148.	8.6	193
77	The neuro-incretin concept. Regulatory Peptides, 2014, 194-195, 3-5.	1.9	2
78	Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. World Journal of Diabetes, 2014, 5, 40.	3.5	46
79	Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia, 2014, 57, 1304-1307.	6.3	39
80	Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor-Deficient Mice. Diabetes, 2014, 63, 101-110.	0.6	64
81	Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro. Diabetes Care, 2014, 37, 2317-2325.	8.6	186
82	Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function. Metabolism: Clinical and Experimental, 2014, 63, 1568-1576.	3.4	8
83	Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial. Diabetologia, 2014, 57, 1807-1811.	6.3	122
84	Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors. Diabetes, 2014, 63, 2196-2202.	0.6	101
85	Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice. Diabetologia, 2014, 57, 801-808.	6.3	7
86	Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia, 2014, 57, 1876-1883.	6.3	69
87	GLP-1 released to the mesenteric lymph duct in mice: Effects of glucose and fat. Regulatory Peptides, 2014, 189, 40-45.	1.9	22
88	Glucagon dynamics during hypoglycaemia and food challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2014, 16, 812-818.	4.4	42
89	Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day. Journal of Diabetes and Its Complications, 2014, 28, 735-741.	2.3	15
90	Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia, 2013, 56, 1752-1760.	6.3	57

#	ARTICLE	IF	CITATIONS
91	Dipeptidyl peptidaseâ€4 inhibitors and cardiovascular risk: aâ€%metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2013, 15, 112-120.	4.4	229
92	Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives. Diabetes and Metabolism, 2013, 39, 195-201.	2.9	55
93	Glucoseâ€lowering effect of the <scp>DPP</scp>â€4 inhibitor sitagliptin after glucose and nonâ€glucose macronutrient ingestion in nonâ€diabetic subjects. Diabetes, Obesity and Metabolism, 2013, 15, 531-537.	4.4	30
94	Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion. Endocrine Connections, 2013, 2, 69-78.	1.9	26
95	GLP-1 receptor agonists in the treatment of Type 2 diabetes. Diabetes Management, 2013, 3, 401-413.	0.5	13
96	Methods and Models for Metabolic Assessment in Mice. Journal of Diabetes Research, 2013, 2013, 1-8.	2.3	47
97	Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. European Diabetes Nursing, 2013, 10, 31-36.	0.2	8
98	Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M). Diabetes Care, 2013, 36, 2543-2550.	8.6	150
99	Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vascular Health and Risk Management, 2013, 9, 155.	2.3	135
100	Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. Vascular Health and Risk Management, 2013, 9, 57.	2.3	25
101	Incretin Hormones and the Up-Regulation of Insulin Secretion in Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1173-1175.	3.6	6
102	Switching From High-Fat to Low-Fat Diet Normalizes Glucose Metabolism and Improves Glucose-Stimulated Insulin Secretion and Insulin Sensitivity But Not Body Weight in C57BL/6J Mice. Pancreas, 2012, 41, 253-257.	1.1	13
103	Inhibition of Dipeptidyl Peptidase-4 (DPP-4): A Target to Treat Type 2 Diabetes. Current Enzyme Inhibition, 2012, 7, 205-217.	0.4	5
104	DPPâ€4 inhibition and islet function. Journal of Diabetes Investigation, 2012, 3, 3-10.	2.4	16
105	Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice. Regulatory Peptides, 2012, 178, 29-35.	1.9	28
106	Plasma lipid fatty acid composition, desaturase activities and insulin sensitivity in Amerindian women. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 176-181.	2.6	12
107	Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3799-3806.	3.6	83
108	Islet nerves in focusâ€defining their neurobiological and clinical role. Diabetologia, 2012, 55, 3152-3154.	6.3	23

#	ARTICLE	IF	CITATIONS
109	Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes. Diabetes Management, 2012, 2, 453-464.	0.5	2
110	Differential Development of Glucose Intolerance and Pancreatic Islet Adaptation in Multiple Diet Induced Obesity Models. Nutrients, 2012, 4, 1367-1381.	4.1	33
111	Using albumin to improve the therapeutic properties of diabetes treatments. Diabetes, Obesity and Metabolism, 2012, 14, 121-129.	4.4	11
112	Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis. Diabetes, Obesity and Metabolism, 2012, 14, 762-767.	4.4	168
113	Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes, Obesity and Metabolism, 2011, 13, 193-203.	4.4	48
114	Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes, Obesity and Metabolism, 2011, 13, 775-783.	4.4	134
115	Dissociated incretin hormone response to protein versus fat ingestion in obese subjects. Diabetes, Obesity and Metabolism, 2011, 13, 863-865.	4.4	15
116	The future of incretin-based therapy: novel avenues—novel targets. Diabetes, Obesity and Metabolism, 2011, 13, 158-166.	4.4	53
117	GLP-1 for type 2 diabetes. Experimental Cell Research, 2011, 317, 1239-1245.	2.6	78
118	Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice. European Journal of Pharmacology, 2011, 663, 80-86.	3.5	26
119	Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?. Current Diabetes Reports, 2011, 11, 83-90.	4.2	22
120	Reply to the letter by P. Guillausseau Regarding “Sulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate Is Not Yet Closed”. Current Diabetes Reports, 2011, 11, 463-463.	4.2	0
121	The Dynamic Incretin Adaptation and Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 620-622.	3.6	5
122	Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 300, R1126-R1133.	1.8	11
123	Incretin Hormone and Insulin Responses to Oral Versus Intravenous Lipid Administration in Humans. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2519-2524.	3.6	161
124	Physiology of Incretins in Health and Disease. Review of Diabetic Studies, 2011, 8, 293-306.	1.3	103
125	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 31.	2.4	36
126	Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on β -cell secretion and insulin clearance in mice. Metabolism: Clinical and Experimental, 2010, 59, 988-992.	3.4	15

#	ARTICLE	IF	CITATIONS
127	Disassociated relation between plasma tumor necrosis factor- α , interleukin-6 and increased body weight in Amerindian women: A long-term prospective study of natural body weight variation and impaired glucose tolerance. <i>Diabetology and Metabolic Syndrome</i> , 2010, 2, 38.	2.7	5
128	Improved insulin sensitivity and islet function after PPAR γ activation in diabetic db/db mice. <i>European Journal of Pharmacology</i> , 2010, 626, 297-305.	3.5	36
129	Study on administration of 1,5-anhydro-D-fructose in C57BL/6J mice challenged with high-fat diet. <i>BMC Endocrine Disorders</i> , 2010, 10, 17.	2.2	5
130	Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 780-789.	4.4	178
131	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, Volume 3, 31-41.	2.4	17
132	Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy. <i>Diabetes Care</i> , 2010, 33, 730-732.	8.6	76
133	Increased β -cell volume in mice fed a high-fat diet: A dynamic study over 12 months. <i>Islets</i> , 2010, 2, 353-356.	1.8	76
134	Secretion and Dipeptidyl Peptidase-4-Mediated Metabolism of Incretin Hormones after a Mixed Meal or Glucose Ingestion in Obese Compared to Lean, Nondiabetic Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 872-878.	3.6	127
135	Incretin Hormone Secretion Over the Day. <i>Vitamins and Hormones</i> , 2010, 84, 203-220.	1.7	41
136	Reappraisal of the intravenous glucose tolerance index for a simple assessment of insulin sensitivity in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009, 296, R1316-R1324.	1.8	24
137	β - and α -Cell Dysfunction in Subjects Developing Impaired Glucose Tolerance. <i>Diabetes</i> , 2009, 58, 726-731.	0.6	57
138	Differential Islet and Incretin Hormone Responses in Morning Versus Afternoon after Standardized Meal in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2887-2892.	3.6	75
139	Altered glucose tolerance in women with deliberate self-harm. <i>Psychoneuroendocrinology</i> , 2009, 34, 878-883.	2.7	6
140	Effects of conjugated linoleic acid plus n-3 polyunsaturated fatty acids on insulin secretion and estimated insulin sensitivity in men. <i>European Journal of Clinical Nutrition</i> , 2009, 63, 778-786.	2.9	24
141	Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 369-385.	46.4	370
142	MODULATION OF FASTED AND POSTPRANDIAL PLASMA LIPIDS IN HEALTHY VOLUNTEERS BY A DIETARY MIXTURE OF OMEGA-3 FATTY ACIDS AND CONJUGATED LINOLEIC ACID. <i>Journal of Food Lipids</i> , 2009, 16, 499-513.	1.0	4
143	Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 157-166.	4.4	258
144	β -Cell research – A decade of rapid growth. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, iv-ix.	4.4	1

#	ARTICLE	IF	CITATIONS
145	Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1236-1243.	3.6	175
146	DPP-4 inhibitors. <i>Insulin</i> , 2009, 4, 15-31.	0.2	6
147	Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin â€“ diabetes control and potential adverse events. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 487-498.	4.7	95
148	Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 1027-1033.	4.4	12
149	Evidence that autonomic mechanisms contribute to the adaptive increase in insulin secretion during dexamethasone-induced insulin resistance in humans. <i>Diabetologia</i> , 2008, 51, 1018-1024.	6.3	25
150	Role of Pituitary Adenylate Cyclase-Activating Polypeptide in the Pancreatic Endocrine System. <i>Annals of the New York Academy of Sciences</i> , 2008, 1144, 28-35.	3.8	34
151	The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. <i>International Journal of Clinical Practice</i> , 2008, 62, 8-14.	1.7	55
152	Effect of a Conjugated Linoleic Acid and Î³ Fatty Acid Mixture on Body Composition and Adiponectin. <i>Obesity</i> , 2008, 16, 1019-1024.	3.0	68
153	Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 593-607.	2.4	84
154	Disturbed β -Cell Function in Mice with β -Cell Specific Overexpression of Human Islet Amyloid Polypeptide. <i>Experimental Diabetes Research</i> , 2008, 2008, 1-4.	3.8	6
155	Incretin and islet hormonal responses to fat and protein ingestion in healthy men. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 295, E779-E784.	3.5	161
156	Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice. <i>Journal of Molecular Endocrinology</i> , 2008, 40, 93-100.	2.5	7
157	The augmenting effect on insulin secretion by oral versus intravenous glucose is exaggerated by high-fat diet in mice. <i>Journal of Endocrinology</i> , 2008, 197, 181-187.	2.6	36
158	Vildagliptin: novel pharmacological approach to treat Type 2 diabetes. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 79-90.	0.2	5
159	Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 383-394.	2.3	63
160	Clinical Measures of Islet Function: Usefulness to Characterize Defects in Diabetes. <i>Current Diabetes Reviews</i> , 2008, 4, 129-145.	1.3	25
161	Insulin Secretion and Insulin Sensitivity in Relation to Fasting Glucose in Healthy Subjects. <i>Diabetes Care</i> , 2007, 30, 644-648.	8.6	18
162	Glucagon-like peptide-1 accelerates the onset of insulin action on glucose disappearance in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E1808-E1814.	3.5	10

#	ARTICLE	IF	CITATIONS
163	Improved Meal-related Insulin Processing Contributes to the Enhancement of B-Cell Function by the DPP-4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes. <i>Hormone and Metabolic Research</i> , 2007, 39, 826-829.	1.5	40
164	Dipeptidyl Peptidase-4 Inhibitors: Clinical data and clinical implications. <i>Diabetes Care</i> , 2007, 30, 1344-1350.	8.6	181
165	DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with β^2 -cell-specific overexpression of human islet amyloid polypeptide. <i>Regulatory Peptides</i> , 2007, 143, 97-103.	1.9	38
166	Role of VIP and PACAP in islet function. <i>Peptides</i> , 2007, 28, 1805-1813.	2.4	81
167	GPR40 is expressed in glucagon producing cells and affects glucagon secretion. <i>Biochemical and Biophysical Research Communications</i> , 2007, 354, 240-245.	2.1	94
168	DPP-4 inhibitors. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2007, 21, 517-533.	4.7	162
169	Temporal and dietary fat contentâ€‘dependent islet adaptation to high-fat feedingâ€‘induced glucose intolerance in mice. <i>Metabolism: Clinical and Experimental</i> , 2007, 56, 122-128.	3.4	37
170	G-protein-coupled receptors and islet functionâ€‘Implications for treatment of type 2 diabetes. , 2007, 116, 437-448.		152
171	Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. <i>Diabetologia</i> , 2007, 50, 1453-1462.	6.3	61
172	A Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischaemic heart disease. <i>Diabetologia</i> , 2007, 50, 1795-1807.	6.3	234
173	GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. <i>Current Diabetes Reports</i> , 2007, 7, 340-347.	4.2	41
174	Omega-3 fatty acids and other polyunsaturated fatty acids and weight control. , 2007, , 281-304.		1
175	Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 431-442.	4.1	74
176	Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006, 1761, 256-260.	2.4	27
177	Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: Partial reversal by insulin. <i>Biochemical and Biophysical Research Communications</i> , 2006, 342, 1174-1177.	2.1	31
178	The insulin response to gastric glucose is reduced in PAC1 and GRP receptor gene deleted mice. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, S17-S21.	2.6	6
179	Contributions from the first SICOD meeting (Stockholm, October 2004). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, S1-S2.	2.6	1
180	Serum cholesteryl fatty acid composition and plasma glucose concentrations in Amerindian women. <i>American Journal of Clinical Nutrition</i> , 2006, 84, 1009-1013.	4.7	25

#	ARTICLE	IF	CITATIONS
181	Incretins and islet function. Current Opinion in Endocrinology, Diabetes and Obesity, 2006, 13, 154-161.	0.6	2
182	Glucagon secretion in relation to insulin sensitivity in healthy subjects. Diabetologia, 2006, 49, 117-122.	6.3	31
183	Glucose-Induced Incretin Hormone Release and Inactivation Are Differently Modulated by Oral Fat and Protein in Mice. Endocrinology, 2006, 147, 3173-3180.	2.8	114
184	Insulin secretion after dietary supplementation with conjugated linoleic acids and n-3 polyunsaturated fatty acids in normal and insulin-resistant mice. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E347-E354.	3.5	40
185	Early and rapid development of insulin resistance, islet dysfunction and glucose intolerance after high-fat feeding in mice overexpressing phosphodiesterase 3B. Journal of Endocrinology, 2006, 189, 629-641.	2.6	26
186	Glucagon Receptor Knockout Mice Display Increased Insulin Sensitivity and Impaired β -Cell Function. Diabetes, 2006, 55, 3463-3469.	0.6	104
187	A novel approach to assess insulin sensitivity reveals no increased insulin sensitivity in mice with a dominant-negative mutant hepatocyte nuclear factor-1 α . American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R131-R137.	1.8	6
188	Inhibition of Dipeptidyl Peptidase-4 (DPP-4) - A Novel Approach to Treat Type 2 Diabetes. Current Enzyme Inhibition, 2005, 1, 65-73.	0.4	27
189	Assessment of insulin secretion in relation to insulin resistance. Current Opinion in Clinical Nutrition and Metabolic Care, 2005, 8, 529-533.	2.5	65
190	Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes, Obesity and Metabolism, 2005, 7, 2-8.	4.4	79
191	Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV. European Journal of Pharmacology, 2005, 509, 211-217.	3.5	45
192	Beta-cell expression of a dominant-negative HNF-1 α compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. European Journal of Pharmacology, 2005, 521, 164-168.	3.5	26
193	Treatment of pancreatic fistula with the somatostatin analogue SMS 201-995. British Journal of Surgery, 2005, 75, 718-718.	0.3	30
194	Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. Diabetologia, 2005, 48, 748-751.	6.3	87
195	What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?. Diabetologia, 2005, 48, 605-607.	6.3	17
196	Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia, 2005, 48, 1700-1713.	6.3	235
197	Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Diabetologia, 2005, 48, 2140-2146.	6.3	49
198	Type 2 Diabetes, Insulin Secretion and β -Cell Mass. Current Molecular Medicine, 2005, 5, 275-286.	1.3	118

#	ARTICLE	IF	CITATIONS
199	Improved Meal-Related Å-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1Year. Diabetes Care, 2005, 28, 1936-1940.	8.6	294
200	Inhibition of Dipeptidyl Peptidase-4 Augments Insulin Secretion in Response to Exogenously Administered Glucagon-Like Peptide-1, Glucose-Dependent Insulinotropic Polypeptide, Pituitary Adenylate Cyclase-Activating Polypeptide, and Gastrin-Releasing Peptide in Mice. Endocrinology, 2005, 146, 2055-2059.	2.8	94
201	A 90-Day Toxicological Evaluation of 1,5-Anhydro-d-Fructose in SpragueÅ©Dawley Rats. Drug and Chemical Toxicology, 2005, 28, 263-272.	2.3	10
202	Exenatide: a novel treatment of Type 2 diabetes. Therapy: Open Access in Clinical Medicine, 2005, 2, 207-222.	0.2	23
203	Exenatide: a novel treatment of Type 2 diabetes. Therapy: Open Access in Clinical Medicine, 2005, 2, 207-222.	0.2	4
204	Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 286, R269-R272.	1.8	87
205	Glucagon-like Peptide-1 and Islet Lipolysis. Hormone and Metabolic Research, 2004, 36, 795-803.	1.5	23
206	GLP-1 Receptor Agonists and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes. Hormone and Metabolic Research, 2004, 36, 867-876.	1.5	202
207	Loss-of-Function Mutation of the Galanin Gene Is Associated with Perturbed Islet Function in Mice. Endocrinology, 2004, 145, 3190-3196.	2.8	70
208	Incretin Hormones and Insulin Secretion. Hormone and Metabolic Research, 2004, 36, 733-734.	1.5	3
209	GLP-1 and Extra-islet Effects. Hormone and Metabolic Research, 2004, 36, 842-845.	1.5	59
210	Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care, 2004, 27, 2874-2880.	8.6	456
211	Î2-Cell-targeted Overexpression of Phosphodiesterase 3B in Mice Causes Impaired Insulin Secretion, Glucose Intolerance, and Deranged Islet Morphology. Journal of Biological Chemistry, 2004, 279, 15214-15222.	3.4	51
212	Beta-Cell-Targeted Expression of a Dominant-Negative Mutant of Hepatocyte Nuclear Factor-1Å in Mice: Diabetes Model with Å-Cell Dysfunction Partially Rescued by Nonglucose Secretagogues. Diabetes, 2004, 53, S92-S96.	0.6	9
213	Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. European Journal of Endocrinology, 2004, 150, 97-104.	3.7	210
214	Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice. European Journal of Pharmacology, 2004, 498, 319-323.	3.5	10
215	Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. Journal of Nutritional Biochemistry, 2004, 15, 579-582.	4.2	40
216	Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 207-212.	0.5	8

#	ARTICLE	IF	CITATIONS
217	Body Adiposity, Insulin, and Leptin in Subgroups of Peruvian Amerindians. High Altitude Medicine and Biology, 2004, 5, 27-31.	0.9	48
218	Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?. Expert Opinion on Investigational Drugs, 2004, 13, 1091-1102.	4.1	176
219	The High-Fat Dietâ€Fed Mouse. Diabetes, 2004, 53, S215-S219.	0.6	837
220	Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2078-2084.	3.6	670
221	Basic toxicology and metabolism studies of 1,5-anhydro-d-fructose using bacteria, cultured mammalian cells, and rodents. Food and Chemical Toxicology, 2004, 42, 1677-1686.	3.6	21
222	Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. Biochemical and Biophysical Research Communications, 2004, 321, 916-921.	2.1	57
223	Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism: Clinical and Experimental, 2004, 53, 624-631.	3.4	90
224	Gut peptides and type 2 diabetes mellitus treatment. Current Diabetes Reports, 2003, 3, 365-372.	4.2	117
225	Acylation stimulating protein stimulates insulin secretion. International Journal of Obesity, 2003, 27, 1037-1043.	3.4	49
226	Dose-Dependent Inhibition by Ghrelin of Insulin Secretion in the Mouse. Endocrinology, 2003, 144, 916-921.	2.8	266
227	Signals adapting the beta cells to changes in insulin sensitivity. International Congress Series, 2003, 1253, 105-113.	0.2	2
228	PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Regulatory Peptides, 2003, 113, 31-39.	1.9	24
229	Postnatally disturbed pancreatic islet cell distribution in human islet amyloid polypeptide transgenic mice. Regulatory Peptides, 2003, 113, 89-94.	1.9	8
230	Characterization of GLP-1 Effects on Î-Cell Function After Meal Ingestion in Humans. Diabetes Care, 2003, 26, 2860-2864.	8.6	71
231	Increased Insulin Sensitivity Is Associated with Reduced Insulin and Glucagon Secretion and Increased Insulin Clearance in Man. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1264-1270.	3.6	30
232	Dual Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Isoproterenol on Lipid Metabolism and Signaling in Primary Rat Adipocytes. Endocrinology, 2003, 144, 5293-5299.	2.8	36
233	Improved Î²-cell function after standardized weight reduction in severely obese subjects. American Journal of Physiology - Endocrinology and Metabolism, 2003, 284, E557-E565.	3.5	111
234	PACAP and the Endocrine Pancreas. Growth Hormone, 2003, , 185-206.	0.2	1

#	ARTICLE	IF	CITATIONS
235	Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 869-875.	8.6	422
236	Abnormal release of incretins and cortisol after oral glucose in subjects with insulin-resistant myotonic dystrophy. <i>European Journal of Endocrinology</i> , 2002, 146, 397-405.	3.7	11
237	Islet Function Phenotype in Gastrin-Releasing Peptide Receptor Gene-Deficient Mice. <i>Endocrinology</i> , 2002, 143, 3717-3726.	2.8	33
238	Quantification of Insulin Secretion in Relation to Insulin Sensitivity in Nondiabetic Postmenopausal Women. <i>Diabetes</i> , 2002, 51, S202-S211.	0.6	43
239	Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. <i>European Journal of Endocrinology</i> , 2002, 146, 717-727.	3.7	173
240	Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose-intolerant mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 283, E738-E744.	3.5	75
241	Differential impairment of glucagon responses to hypoglycemia, neuroglycopenia, arginine, and carbachol in alloxan-diabetic mice. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 12-19.	3.4	11
242	Effects of chemical sympathectomy by means of 6-hydroxydopamine on insulin secretion and islet morphology in alloxan-diabetic mice. <i>Cell and Tissue Research</i> , 2002, 307, 203-209.	2.9	17
243	The neuropeptide PACAP contributes to the glucagon response to insulin-induced hypoglycaemia in mice. <i>Acta Physiologica Scandinavica</i> , 2002, 175, 25-28.	2.2	23
244	Autonomic neuropathy is associated with impaired pancreatic polypeptide and neuropeptide Y responses to insulin-induced hypoglycaemia in Type I diabetic patients. <i>Diabetologia</i> , 2002, 45, 1043-1044.	6.3	13
245	The Cephalic Insulin Response to Meal Ingestion in Humans Is Dependent on Both Cholinergic and Noncholinergic Mechanisms and Is Important for Postprandial Glycemia. <i>Diabetes</i> , 2001, 50, 1030-1038.	0.6	255
246	Overweight is associated with lower serum leptin in Peruvian Indian than in Caucasian women: A dissociation contributing to low blood pressure?. <i>Metabolism: Clinical and Experimental</i> , 2001, 50, 325-329.	3.4	22
247	Impaired Incretin Response After a Mixed Meal Is Associated With Insulin Resistance in Nondiabetic Men. <i>Diabetes Care</i> , 2001, 24, 1640-1645.	8.6	197
248	Contribution to glucose tolerance of insulin-independent vs. insulin-dependent mechanisms in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2001, 281, E693-E703.	3.5	102
249	Differential Effects of Glucagon-like Peptide-1 (7-36)Amide Versus Cholecystokinin on Arginine-Induced Islet Hormone Release In Vivo and In Vitro. <i>Pancreas</i> , 2001, 22, 58-64.	1.1	14
250	Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. <i>Diabetologia</i> , 2001, 44, 1998-2003.	6.3	83
251	Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. <i>Acta Physiologica Scandinavica</i> , 2001, 171, 161-167.	2.2	28
252	Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. <i>Journal of Internal Medicine</i> , 2001, 250, 81-87.	6.0	26

#	ARTICLE	IF	CITATIONS
253	The Neuropeptide Pituitary Adenylate Cyclase-Activating Polypeptide and Islet Function. <i>Diabetes</i> , 2001, 50, 1959-1969.	0.6	80
254	Diurnal variation in circulating leptin is dependent on gender, food intake and circulating insulin in mice. <i>Acta Physiologica Scandinavica</i> , 2000, 169, 325-331.	2.2	80
255	The negative association between serum free testosterone and leptin is dependent on insulin-like growth factor-binding protein 1 in healthy young and middle-aged men. <i>Clinical Endocrinology</i> , 2000, 52, 493-498.	2.4	4
256	Pharmacokinetics of human leptin in mice and rhesus monkeys. <i>International Journal of Obesity</i> , 2000, 24, 1579-1585.	3.4	36
257	Augmented Insulinotropic Action of Arachidonic Acid through the Lipoxigenase Pathway in the Obese Zucker Rat. <i>Obesity</i> , 2000, 8, 475-480.	4.0	17
258	1,5-Anhydro-d-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice. <i>European Journal of Pharmacology</i> , 2000, 397, 219-225.	3.5	27
259	Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. <i>European Journal of Pharmacology</i> , 2000, 404, 239-245.	3.5	184
260	Phospholipase A ² and Its Potential Regulation of Islet Function. <i>International Journal of Gastrointestinal Cancer</i> , 2000, 27, 01-12.	0.4	13
261	Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women. <i>Diabetologia</i> , 2000, 43, 194-202.	6.3	62
262	Autonomic regulation of islet hormone secretion - Implications for health and disease. <i>Diabetologia</i> , 2000, 43, 393-410.	6.3	776
263	Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 278, E684-E691.	3.5	30
264	Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 279, E956-E962.	3.5	61
265	PACAP contributes to insulin secretion after gastric glucose gavage in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2000, 279, R424-R432.	1.8	29
266	Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. <i>Diabetes Care</i> , 2000, 23, 650-657.	8.6	88
267	Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1043-1048.	3.6	64
268	Differential changes in islet amyloid polypeptide (amylin) and insulin mRNA expression after high-fat diet-induced insulin resistance in C57BL/6J mice. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 1518-1522.	3.4	21
269	Islet Amyloid and Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2000, 343, 411-419.	27.0	488
270	The Effects of PACAP on Insulin Secretion and Glucose Disposal Are Altered by Adrenalectomy in Mice. <i>Annals of the New York Academy of Sciences</i> , 2000, 921, 251-258.	3.8	9

#	ARTICLE	IF	CITATIONS
271	Intraperitoneal PACAP Administration Decreases Blood Glucose in GK Rats, and in Normal and High Fat Diet Mice. <i>Annals of the New York Academy of Sciences</i> , 2000, 921, 259-263.	3.8	39
272	PACAP27 Sensitizes Glucose Induced Insulin Secretion in INS-1 Cells. <i>Annals of the New York Academy of Sciences</i> , 2000, 921, 456-459.	3.8	1
273	PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. <i>Journal of Clinical Investigation</i> , 2000, 105, 1307-1315.	8.2	175
274	Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1043-1048.	3.6	59
275	Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1999, 277, E996-E1004.	3.5	44
276	Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1999, 277, E93-E102.	3.5	32
277	Leptin inhibits insulin secretion induced by cellular cAMP in a pancreatic B cell line (INS-1 cells). <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999, 277, R959-R966.	1.8	37
278	Relative Hyperproinsulinemia as a Sign of Islet Dysfunction in Women with Impaired Glucose Tolerance ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2068-2074.	3.6	42
279	Plasma leptin and insulin in C57Bl/6J mice on a high-fat diet: relation to subsequent changes in body weight. <i>Acta Physiologica Scandinavica</i> , 1999, 165, 233-240.	2.2	53
280	Lowering of circulating insulin and leptin is closely associated following weight reduction after vertical banded gastroplasty in obese women. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 53-55.	4.4	13
281	Leptin increases circulating glucose, insulin and glucagon via sympathetic neural activation in fasted mice. <i>International Journal of Obesity</i> , 1999, 23, 660-665.	3.4	23
282	Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. <i>Diabetologia</i> , 1999, 42, 936-943.	6.3	63
283	Relation Between Malnutrition and Development of Diabetes Mellitus. <i>International Journal of Gastrointestinal Cancer</i> , 1999, 26, 125-130.	0.4	3
284	Islet neuronal abnormalities associated with impaired insulin secretion in type 2 diabetes in the Chinese hamster. <i>Regulatory Peptides</i> , 1999, 82, 71-79.	1.9	13
285	Regulation of insulin secretion by nerves and neuropeptides. <i>Annals of the Academy of Medicine, Singapore</i> , 1999, 28, 99-104.	0.4	11
286	Protein Kinase A Inhibition and PACAP-Induced Insulin Secretion in HIT-T15 Cells. <i>Annals of the New York Academy of Sciences</i> , 1998, 865, 441-444.	3.8	14
287	Pituitary Adenylate Cyclase Activating Polypeptide Stimulates Insulin Secretion in a Glucose-Dependent Manner In Vivo. <i>Annals of the New York Academy of Sciences</i> , 1998, 865, 466-470.	3.8	1
288	Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes. <i>BioEssays</i> , 1998, 20, 642-651.	2.5	113

#	ARTICLE	IF	CITATIONS
289	Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. <i>Diabetologia</i> , 1998, 41, 772-777.	6.3	90
290	Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice. <i>Diabetologia</i> , 1998, 41, 1374-1380.	6.3	40
291	PACAP and PACAP receptors in insulin producing tissues: localization and effects. <i>Regulatory Peptides</i> , 1998, 74, 167-175.	1.9	66
292	Different Sensitivity to the Cytotoxic Action of IAPP Fibrils in Two Insulin-Producing Cell Lines, HIT-T15 and RINm5F Cells. <i>Biochemical and Biophysical Research Communications</i> , 1998, 251, 888-893.	2.1	34
293	Potentiated β -cell response to non-glucose stimuli in insulin-resistant C57BL/6J mice. <i>European Journal of Pharmacology</i> , 1998, 350, 243-250.	3.5	30
294	Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice. <i>European Journal of Endocrinology</i> , 1998, 139, 461-467.	3.7	92
295	Age-Related Reduction in Glucose Elimination Is Accompanied by Reduced Glucose Effectiveness and Increased Hepatic Insulin Extraction in Man1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 3350-3356.	3.6	48
296	Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. <i>Diabetes</i> , 1998, 47, 995-1005.	0.6	196
297	Evidence for Contribution by Increased Cytoplasmic Na ⁺ to the Insulinotropic Action of PACAP38 in HIT-T15 Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 32602-32607.	3.4	15
298	Insulin secretion by gastrin-releasing peptide in mice: ganglionic versus direct islet effect. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 274, E124-E129.	3.5	11
299	PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 274, E834-E842.	3.5	39
300	Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1998, 274, R1482-R1491.	1.8	96
301	Age-Related Reduction in Glucose Elimination Is Accompanied by Reduced Glucose Effectiveness and Increased Hepatic Insulin Extraction in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 3350-3356.	3.6	36
302	Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 473-478.	3.6	124
303	Differential effect of insulin treatment on islet amyloid polypeptide (amylin) and insulin gene expression in streptozotocin-induced diabetes in rats. <i>Journal of Endocrinology</i> , 1997, 152, 495-501.	2.6	6
304	Pituitary Adenylate Cyclase-Activating Polypeptide Stimulates Insulin and Glucagon Secretion in Humans*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3093-3098.	3.6	68
305	Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. <i>European Journal of Endocrinology</i> , 1997, 137, 127-131.	3.7	47
306	GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions. <i>Diabetes Care</i> , 1997, 20, 1874-1879.	8.6	76

#	ARTICLE	IF	CITATIONS
307	Activation of Autonomic Nerves and the Adrenal Medulla Contributes to Increased Glucagon Secretion During Moderate Insulin-Induced Hypoglycemia in Women. <i>Diabetes</i> , 1997, 46, 801-807.	0.6	77
308	No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes. <i>European Journal of Endocrinology</i> , 1997, 137, 643-649.	3.7	13
309	Galanin Exerts Dual Action on Inositol-Specific Phospholipase C Activity in Isolated Pancreatic Islets.. <i>Endocrine Journal</i> , 1997, 44, 283-288.	1.6	3
310	Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat dietâ€”induced insulin resistance in C57BL/6J mice. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 97-106.	3.4	117
311	Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 273, E701-E707.	3.5	39
312	Regulation of plasma leptin in mice: influence of age, high-fat diet, and fasting. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1997, 273, R113-R120.	1.8	137
313	Regulation of circulating leptin in humans. <i>Endocrine</i> , 1997, 7, 1-8.	2.2	70
314	Function of reduced-size liver transplant in the rat. <i>Research in Experimental Medicine</i> , 1997, 197, 91-99.	0.7	2
315	Intraoperative Secretion of Intact Parathyroid Hormone and Amino-Terminal Parathyroid Hormone Fragments from Normal Parathyroid Glands Associated with Solitary Parathyroid Adenoma. <i>World Journal of Surgery</i> , 1997, 21, 30-35.	1.6	9
316	Glucagonâ€”like peptideâ€”1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. <i>Acta Physiologica Scandinavica</i> , 1997, 160, 413-422.	2.2	102
317	Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 473-478.	3.6	100
318	Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. <i>Diabetes</i> , 1997, 46, 801-807.	0.6	19
319	Islet dysfunction in obese women with impaired glucose tolerance. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 502-509.	3.4	43
320	Effects of glucagon-like peptide-I on glucose turnover in rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1996, 270, E1015-E1021.	3.5	13
321	Stimulation of somatostatin secretion by 3-O-methylglucose in the perfused dog pancreas. <i>International Journal of Gastrointestinal Cancer</i> , 1996, 20, 103-107.	0.4	3
322	Glucagon-like peptide-1(7-36) amide and cytoplasmic calcium in insulin producing cells. <i>Acta Physiologica Scandinavica</i> , 1996, 157, 333-341.	2.2	6
323	Pancreastatin modulates glucose-stimulated insulin secretion from the perfused rat pancreas. <i>Acta Physiologica Scandinavica</i> , 1996, 158, 63-70.	2.2	14
324	Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. <i>Diabetologia</i> , 1996, 39, 1099-1107.	6.3	60

#	ARTICLE	IF	CITATIONS
325	Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse. <i>Diabetologia</i> , 1996, 39, 383-390.	6.3	14
326	Plasma neuropeptide Y in impaired glucose tolerance. <i>Acta Diabetologica</i> , 1996, 33, 295-297.	2.5	1
327	Peptide YY does not inhibit glucose-stimulated insulin secretion in humans. <i>European Journal of Endocrinology</i> , 1996, 134, 362-365.	3.7	25
328	Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet. <i>Diabetes Care</i> , 1996, 19, 843-848.	8.6	107
329	Signaling mechanisms underlying the insulinotropic effect of pituitary adenylate cyclase-activating polypeptide in HIT-T15 cells.. <i>Endocrinology</i> , 1996, 137, 2791-2798.	2.8	43
330	Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats. <i>Diabetologia</i> , 1996, 39, 649-657.	6.3	3
331	Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. <i>Diabetologia</i> , 1996, 39, 1099-1107.	6.3	5
332	Signaling mechanisms underlying the insulinotropic effect of pituitary adenylate cyclase-activating polypeptide in HIT-T15 cells. <i>Endocrinology</i> , 1996, 137, 2791-2798.	2.8	19
333	Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse. <i>Diabetologia</i> , 1996, 39, 383-390.	6.3	0
334	Effects of GLP-1 and 2,5-anhydro-D-mannitol on insulin secretion and plasma glucose in mice. <i>Endocrine Research</i> , 1995, 21, 583-594.	1.2	9
335	Effects of Arginine on the Secretion of Insulin and Islet Amyloid Polypeptide in Humans. <i>Pancreas</i> , 1995, 11, 201-205.	1.1	18
336	Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle-aged women. <i>Journal of Internal Medicine</i> , 1995, 237, 537-541.	6.0	52
337	Insulinotropic action of truncated glucagon-like peptide-1 in mice. <i>Acta Physiologica Scandinavica</i> , 1995, 153, 205-206.	2.2	26
338	Glucagon secretory response to hypoglycaemia, adrenaline and carbachol in streptozotocindiabetic rats. <i>Acta Physiologica Scandinavica</i> , 1995, 155, 215-221.	2.2	17
339	Long-term effects of alloxan in mice. <i>International Journal of Gastrointestinal Cancer</i> , 1995, 17, 197-201.	0.4	20
340	Antidiabetogenic action of truncated glucagon-like peptide-1 in mice. <i>Endocrine</i> , 1995, 3, 367-369.	2.2	6
341	Effects of Minor Increase in Serum Calcium on the Immunoheterogeneity of Parathyroid Hormone in Healthy Subjects and in Patients with Primary Hyperparathyroidism. <i>Hormone Research</i> , 1995, 43, 294-299.	1.8	2
342	Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 1778-1782.	3.6	36

#	ARTICLE	IF	CITATIONS
343	Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. <i>Molecular and Cellular Endocrinology</i> , 1995, 114, 101-109.	3.2	34
344	Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. <i>Diabetologia</i> , 1995, 38, 395-402.	6.3	6
345	Involvement of capsaicin-sensitive nerves in regulation of insulin secretion and glucose tolerance in conscious mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1994, 267, R1071-R1077.	1.8	30
346	Mechanisms underlying the insulinostatic effect of peptide YY in mouse pancreatic islets. <i>Diabetologia</i> , 1994, 37, 871-878.	6.3	3
347	Muscarinic receptor subtypes in carbachol-estimated insulin and glucagon secretion in the mouse. <i>Autonomic and Autacoid Pharmacology</i> , 1993, 13, 439-446.	0.6	22
348	Different mechanisms are involved in neuropeptide Y-induced pancreatic vasoconstriction and inhibition of insulin secretion. <i>European Journal of Pharmacology</i> , 1993, 236, 69-74.	3.5	20
349	Potential Clinical Use of the EDTA-Infusion Test. <i>Clinical Chemistry and Laboratory Medicine</i> , 1993, 31, 353-8.	2.3	0
350	CHOLECYSTOKININ (CCK 33) CAN STIMULATE PANCREATIC SECRETION BY A LOCAL INTESTINAL MECHANISM IN THE PIG . <i>Biomedical Research</i> , 1993, 14, 217-221.	0.9	14
351	Interferon-alpha in the treatment of neuroendocrine tumours: effect on glucose tolerance and glucose-stimulated insulin secretion. <i>The European Journal of Surgery</i> , 1993, 159, 209-12.	0.9	2
352	Capacity to secrete islet hormones after subtotal pancreatectomy for pancreatic cancer. <i>The European Journal of Surgery</i> , 1993, 159, 223-7.	0.9	12
353	Antidiabetogenic Effect of Glucagon-like Peptide-1 (7-36)amide in Normal Subjects and Patients with Diabetes Mellitus. <i>New England Journal of Medicine</i> , 1992, 326, 1316-1322.	27.0	860
354	Cholecystokinin and the Regulation of Insulin Secretion. <i>Scandinavian Journal of Gastroenterology</i> , 1992, 27, 161-165.	1.5	51
355	Plasma neuropeptide Y (NPY) and galanin before and during exercise in type 1 diabetic patients with autonomic dysfunction. <i>Diabetes Research and Clinical Practice</i> , 1992, 15, 219-226.	2.8	23
356	Inhibitory effect of D-myo-inositol-1,2,6-trisphosphate on glucose-stimulated insulin secretion in the mouse. <i>Neuropeptides</i> , 1992, 21, 163-166.	2.2	6
357	Neonatal capsaicin-treatment in mice: effects on pancreatic peptidergic nerves and 2-deoxy-d-glucose-induced insulin and glucagon secretion. <i>Journal of the Autonomic Nervous System</i> , 1992, 39, 51-59.	1.9	39
358	Pituitary adenylate cyclase-activating polypeptide (PACAP): occurrence in rodent pancreas and effects on insulin and glucagon secretion in the mouse. <i>Cell and Tissue Research</i> , 1992, 269, 275-279.	2.9	126
359	Localization of calcitonin gene-related peptide and islet amyloid polypeptide in the rat and mouse pancreas. <i>Cell and Tissue Research</i> , 1992, 269, 315-322.	2.9	41
360	Galanin inhibits tolbutamide-stimulated insulin secretion in the perfused pig pancreas. <i>Diabetes Research</i> , 1992, 19, 59-62.	0.1	0

#	ARTICLE	IF	CITATIONS
361	Recurrent laryngeal nerve palsy after thyroid and parathyroid surgery. Experience from Lund University. <i>Thyroidology</i> , 1992, 4, 87-9.	0.1	2
362	Treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon. <i>Anticancer Research</i> , 1992, 12, 129-33.	1.1	12
363	Tolerance to long-term treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon. <i>Anticancer Research</i> , 1992, 12, 881-4.	1.1	7
364	Inhibition by galanin and by high K ⁺ of human basophil histamine release triggered by calcium ionophores but not responses induced by anti-��gE, chemotactic peptide or phorbol ester. <i>British Journal of Pharmacology</i> , 1991, 103, 1381-1384.	5.4	1
365	Effects of helospectin I on insulin and glucagon secretion in the mouse. <i>British Journal of Pharmacology</i> , 1991, 102, 916-918.	5.4	5
366	Effects of amidated rat islet amyloid polypeptide on glucose-stimulated insulin secretion in vivo and in vitro in rats. <i>European Journal of Pharmacology</i> , 1991, 192, 443-445.	3.5	32
367	Studies on the mechanism by which galanin inhibits insulin secretion in islets. <i>European Journal of Pharmacology</i> , 1991, 205, 21-27.	3.5	27
368	Effects of neuropeptide Y on insulin and glucagon secretion in the pig. <i>Neuropeptides</i> , 1991, 20, 49-55.	2.2	12
369	Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man. <i>Diabetes Research and Clinical Practice</i> , 1991, 13, 153-161.	2.8	46
370	GLP-1 and GLP-17-36 Amide. <i>Pancreas</i> , 1991, 6, 208-215.	1.1	67
371	Presence of galanin in human pancreatic nerves and inhibition of insulin secretion from isolated human islets. <i>Cell and Tissue Research</i> , 1991, 264, 263-267.	2.9	47
372	Galanin-immunoreactive nerves in the mouse and rat pancreas. <i>Cell and Tissue Research</i> , 1991, 264, 363-368.	2.9	47
373	Contribution of galanin to stress��induced impairment of insulin secretion in swimming mice. <i>Acta Physiologica Scandinavica</i> , 1991, 143, 145-152.	2.2	20
374	Regulatory peptides in the thyroid gland��a review on their localization and function. <i>Acta Endocrinologica</i> , 1991, 124, 225-32.	0.0	12
375	GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. <i>Pancreas</i> , 1991, 6, 208-15.	1.1	16
376	Galanin of the homologous species inhibits insulin secretion in the rat and in the pig. <i>Acta Physiologica Scandinavica</i> , 1990, 139, 591-596.	2.2	35
377	Calcitonin gene-related peptide (CGRP) and amylin and the endocrine pancreas. <i>International Journal of Gastrointestinal Cancer</i> , 1990, 6, 1-15.	0.4	27
378	Galanin is co-localized with noradrenaline and neuropeptide Y in dog pancreas and celiac ganglion. <i>Cell and Tissue Research</i> , 1990, 261, 49-58.	2.9	82

#	ARTICLE	IF	CITATIONS
379	Subtotal pancreatectomy with stapling the pancreatic remnant. <i>Langenbecks Archiv Fur Chirurgie</i> , 1990, 375, 359-61.	0.2	1
380	Effects of galanin and calcitonin gene-related peptide on insulin and glucagon secretion in man. <i>European Journal of Endocrinology</i> , 1990, 123, 591-597.	3.7	27
381	Effects of galanin and calcitonin gene-related peptide on insulin and glucagon secretion in man. <i>Acta Endocrinologica</i> , 1990, 123, 591-7.	0.0	8
382	Pancreastatin inhibits insulin secretion and exocrine pancreatic secretion in the pig. <i>Diabetes Research</i> , 1990, 14, 93-6.	0.1	3
383	Calcium stimulates the release of calcitonin gene-related peptide from the canine thyroid. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1989, 256, E597-E599.	3.5	1
384	Cysteamine and the endocrine pancreas: Immunocytochemical, immunochemical, and functional aspects. <i>Cell and Tissue Research</i> , 1989, 256, 159-66.	2.9	7
385	Effects of δ^2 -endorphin, met-enkephalm, and dynorphin a on basal and stimulated insulin secretion in the mouse. <i>International Journal of Gastrointestinal Cancer</i> , 1989, 5, 165-78.	0.4	16
386	Effects of galanin on insulin and glucagon secretion in the rat. <i>International Journal of Gastrointestinal Cancer</i> , 1989, 4, 335-344.	0.4	24
387	Effects of calcitonin, katalcalcin, and calcitonin gene-related peptide on basal and TSH-stimulated thyroid hormone secretion in the mouse. <i>Acta Physiologica Scandinavica</i> , 1989, 135, 133-137.	2.2	13
388	Effects of VIP and helodermin on thyroid hormone secretion in the mouse. <i>Neuropeptides</i> , 1989, 13, 59-64.	2.2	12
389	GABA inhibits thyroid hormone secretion in the mouse. <i>Thyroidology</i> , 1989, 1, 105-8.	0.1	5
390	Insulin secretion in neonatally streptozotocin-injected mice. <i>Diabetes Research</i> , 1989, 11, 185-9.	0.1	2
391	Reduction of secretion from a small-bowel fistula by somatostatin. Case report. <i>Acta Chirurgica Scandinavica</i> , 1989, 155, 205-8.	0.2	1
392	Effects of gastrin-releasing peptide on basal and stimulated thyroid hormone secretion in the mouse. <i>Acta Endocrinologica</i> , 1989, 120, 245-9.	0.0	0
393	Cholecystokinin (CCK)-33 Stimulates Insulin Secretion from the Perfused Rat Pancreas: Studies on the Structure-Activity Relationship. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1988, 63, 42-45.	0.0	16
394	Effects of pancreatic noradrenaline infusion on basal and stimulated islet hormone secretion in the dog. <i>Acta Physiologica Scandinavica</i> , 1988, 132, 143-150.	2.2	12
395	The effects of epinephrine on islet hormone secretion in the dog. <i>International Journal of Gastrointestinal Cancer</i> , 1988, 3, 375-388.	0.4	6
396	Galanin and the endocrine pancreas. <i>FEBS Letters</i> , 1988, 229, 233-237.	2.8	59

#	ARTICLE	IF	CITATIONS
397	Pancreastatin Inhibits Insulin Secretion and Stimulates Glucagon Secretion in Mice. Diabetes, 1988, 37, 281-285.	0.6	64
398	ANF inhibits glucose-stimulated insulin secretion in mouse and rat. American Journal of Physiology - Endocrinology and Metabolism, 1988, 255, E579-E582.	3.5	5
399	Plasmapheresis and haemodialysis in a case of septic cholangitis complicated by hepatic and renal failure. Case report. Acta Chirurgica Scandinavica, 1988, 154, 157-9.	0.2	3
400	Basal Release of Insulin and Glucagon*. Endocrinology, 1987, 121, 323-331.	2.8	126
401	Î±-Adrenoceptor Blockade by Phentolamine Inhibits Î²-Adrenergically and Cholinergically Induced Glucagon Secretion in the Mouse. Hormone and Metabolic Research, 1987, 19, 600-603.	1.5	11
402	The mechanism of 2-deoxy-glucose-induced insulin secretion in the mouse. Autonomic and Autacoid Pharmacology, 1987, 7, 135-144.	0.6	22
403	Gastrin Releasing Peptide (GRP): Effects on basal and stimulated insulin and glucagon secretion in the mouse. Peptides, 1987, 8, 55-60.	2.4	37
404	Inhibition of 2-deoxy-glucose-induced glucagon secretion by muscarinic and Î±-adrenoceptor blockade in the mouse. Diabetes Research and Clinical Practice, 1987, 3, 239-242.	2.8	12
405	Neuropeptide Y: Intrapancreatic neuronal localization and effects on insulin secretion in the mouse. Cell and Tissue Research, 1987, 248, 43-48.	2.9	110
406	Kinetics of Radioiodine Released from Prelabelled Thyroid Gland <i>in Vivo</i>: Influence of Propylthiouracil. Basic and Clinical Pharmacology and Toxicology, 1987, 61, 69-71.	0.0	4
407	Galanin: effects on basal and stimulated insulin and glucagon secretion in the mouse. Acta Physiologica Scandinavica, 1987, 129, 305-309.	2.2	64
408	Insulin and C-peptide Secretory Responses to Glucagon in Man: Studies on the Dose-Response Relationships. Acta Medica Scandinavica, 1987, 221, 185-190.	0.0	22
409	Effects of Î±1- and Î±2-Adrenoceptor Stimulation and Blockade on Plasma Insulin Levels in the Mouse. Pancreas, 1986, 1, 415-420.	1.1	33
410	Neuropeptidergic versus cholinergic and adrenergic regulation of islet hormone secretion. Diabetologia, 1986, 29, 827-836.	6.3	274
411	Potential of glucose-induced insulin secretion in the perfused rat pancreas by porcine GIP (gastric) Tj ETQq1 1 0.784314 rgBT /Ove 1986, 127, 323-326.	2.2	11
412	The Mechanism of Vagal Nerve Stimulation of Glucagon and Insulin Secretion in the Dog*. Endocrinology, 1986, 118, 1551-1557.	2.8	117
413	Hyperthyroidism and Glucose Intolerance. Acta Medica Scandinavica, 1986, 220, 5-14.	0.0	9
414	Effects of Six Cholecystokinin (CCK) Fragments on Insulin Secretion in the Mouse. Acta Pharmacologica Et Toxicologica, 1986, 58, 115-120.	0.0	13

#	ARTICLE	IF	CITATIONS
415	Effects of α - and β -adrenoceptor stimulation on $^{45}\text{Ca}^{2+}$ efflux and insulin secretion from perfused rat islets. <i>Acta Physiologica Scandinavica</i> , 1985, 124, 381-389.	2.2	9
416	Effects of α -adrenoceptor blockade by phentolamine on basal and stimulated insulin secretion in the mouse. <i>Acta Physiologica Scandinavica</i> , 1985, 125, 211-217.	2.2	33
417	Effect of Dietary Fibre on Blood Glucose, Plasma Immunoreactive Insulin, C-peptide and GIP Responses in non Insulin Dependent (Type 2) Diabetics and Controls. <i>Acta Medica Scandinavica</i> , 1984, 215, 205-213.	0.0	40
418	Effect of Sulfonylurea on Glucose, Insulin and C-peptide Responses to a Meal Stimulus in a Patient with Type 2 Diabetes and Liver Disease. <i>Acta Medica Scandinavica</i> , 1984, 215, 487-491.	0.0	1
419	Interaction of gastric inhibitory polypeptide (GIP) and cholecystokinin (CCK-8) with basal and stimulated insulin secretion in mice. <i>European Journal of Endocrinology</i> , 1983, 102, 96-102.	3.7	32
420	Influences of Gastro-Intestinal Polypeptides and Glucose on Glucagon Secretion Induced by Cholinergic Stimulation. <i>Hormone and Metabolic Research</i> , 1982, 14, 529-532.	1.5	14
421	Modulation of basal insulin secretion in the obese, hyperglycemic mouse. <i>Metabolism: Clinical and Experimental</i> , 1982, 31, 172-179.	3.4	31
422	VIP-stimulated thyroid hormone secretion: Effects of other neuropeptides and α - or β -adrenoceptor blockade. <i>Acta Physiologica Scandinavica</i> , 1982, 114, 471-473.	2.2	26
423	Enhancement of insulin secretion during selective blockade of β_1 , α - and β_2 -adrenoceptors in the rat: Effects of somatostatin. <i>Acta Physiologica Scandinavica</i> , 1982, 115, 257-260.	2.2	13
424	Glucagon immunoreactivity in plasma from normal and dystrophic mice. <i>Diabetologia</i> , 1982, 22, 258-263.	6.3	68
425	Effects of autonomic blockade by methylatropine and optical isomers of propranolol on plasma insulin levels in the basal state and after stimulation. <i>Acta Physiologica Scandinavica</i> , 1981, 112, 57-63.	2.2	28
426	GIP-like immunoreactivity in glucagon cells Interactions between GIP and glucagon on insulin release. <i>Acta Physiologica Scandinavica</i> , 1981, 112, 233-242.	2.2	24
427	Insulin secretion induced by glucose and by stimulation of β_2 -adrenoceptors in the rat. Different sensitivity to somatostatin. <i>Acta Physiologica Scandinavica</i> , 1981, 112, 421-426.	2.2	6
428	Adrenalectomy and chemical sympathectomy by 6-hydroxydopamine. Effects on basal and stimulated insulin secretion. <i>Pflügers Archiv European Journal of Physiology</i> , 1981, 390, 17-21.	2.8	9
429	Immunoreactive Insulin and C-peptide Responses to Various Insulin Secretory Stimuli in Subjects with Type 2 Diabetes and in Control Subjects during Continuous Glucose Monitoring. <i>Acta Medica Scandinavica</i> , 1981, 210, 337-348.	0.0	12
430	Effects of vasoactive intestinal polypeptide (VIP), secretin and gastrin on insulin secretion in the mouse. <i>Diabetologia</i> , 1981, 21, 54-59.	6.3	3
431	Effects of glucagon and pentagastrin on glibenclamide-induced insulin release. <i>Acta Physiologica Scandinavica</i> , 1980, 109, 261-264.	2.2	1
432	Somatostatin, Pancreatic Polypeptide, Substance P, and Neurotensin: Cellular Distribution and Effects on Stimulated Insulin Secretion in the Mouse*. <i>Endocrinology</i> , 1979, 104, 832-838.	2.8	77

#	ARTICLE	IF	CITATIONS
433	Failure of somatostatin to eliminate the glucagon release induced by baroreceptor unloading in the cat. Acta Physiologica Scandinavica, 1978, 103, 478-480.	2.2	4